Editorial: Pharmacology of autoimmune and neuroinflammatory disease from a preclinical and clinical perspective

Martin Šíma; Andrea Laslop; John Joseph Borg; Silvester Poništ; Daniela Melchiorri; František Dráfi

doi:10.3389/fphar.2023.1228406

Editorial: Pharmacology of autoimmune and neuroinflammatory disease from a preclinical and clinical perspective

Front Pharmacol. 2023 Jun 13:14:1228406. doi: 10.3389/fphar.2023.1228406. eCollection 2023.

Authors

Martin Šíma¹, Andrea Laslop², John Joseph Borg^{3

4}, Silvester Poništ⁵, Daniela Melchiorri⁶, František Dráfi^{5

7}

Affiliations

¹ Institute of Pharmacology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czechia.
² Agency for Health and Food Safety (AGES), Vienna, Austria.
³ Malta Medicines Authority, Sir Temi Żammit Buildings, Malta Life Sciences Park, San Gwann, Malta.
⁴ School of Pharmacy, Department of Biology, University of Tor Vergata, Rome, Italy.
⁵ Institute of Experimental Pharmacology and Toxicology, Centre of Experimental Medicine SAS Bratislava, Bratislava, Slovakia.
⁶ Department of Physiology and Pharmacology, Sapienza University, Rome, Italy.
⁷ State Institute for Drug Control, Bratislava, Slovakia.

No abstract available

Keywords: Alzheimer's disease; Behcet’s disease; RIPK2; Sjögren’s syndrome; immunopharmacology; immunotargets; neuroinflammation; oligodeoxynucleotides.

Publication types

Editorial

Grants and funding

MŠ. acknowledges the support by the Charles University project Cooperatio (research area PHAR). FD acknowledges the assist of MVTS Grant No. CA21139“3Rs concepts to improve the quality of biomedical science (IMPROVE),” the VEGA Grant Nos 2/0091/23 and VEGA 2/0126/23 as well as the SIDC Bratislava, Slovakia.